Experience

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca

March 17, 2025

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Charity Williams
Partner, San Diego
Simon Amies
Partner, London
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Charlie Lightfoot
Partner, London
Alessandra Murata
Partner, Palo Alto
Guadalupe Sampedro
Partner, London
Stella Sarma
Partner, Brussels
Leo Spicer-Phelps
Partner, London
Nicola Squire
Partner, London
Chris Stack
Partner, London
Jeffrey J. Tolin
Partner, New York
David Wilson
Partner, London
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Jack Jones
Special Counsel, London
Dillon Martinson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Julie Wicklund
Special Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Kafeel Azher
Associate, London
Sarah Buchik
Associate, New York
Mari Dugas
Associate, Washington, DC
Michael Fernando
Associate, London
Athina Gaki
Associate, Brussels
Elaine Huang
Associate, Palo Alto
Mark Jones
Associate, London
Eerik Kukebal
Associate, London
Chris Lynn
Associate, London
Morgan McCormack
Associate, London
Daniel Millard
Associate, London
Lindsey O'Crump
Associate, Washington, DC
Alexandra Paterson
Associate, London
Zhijing Yu
Associate, Singapore
Kevin Gurley
Quantitative Analyst, New York

Related Practices & Industries

Laekna Announces Clinical Collaboration With Lilly

November 26, 2024

Cooley advised Laekna (HKSE: 2105.HK), global biotech company focused on novel drug development for metabolic and cancer diseases, on its clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a treatment for obesity.

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Bin Wang
Special Counsel, Palo Alto
Zack Gong
Associate, Shanghai
David Burns
Special Counsel, Washington, DC
Tonny Yu
Associate, Hong Kong
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Kura Oncology Announces Global Strategic Collaboration With Kyowa Kirin

November 20, 2024

Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia and other hematologic malignancies.

Read more

Related contacts

Charity Williams
Partner, San Diego
Jonathan Kaufman
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Amanda Pacheco
Associate, Palo Alto
Howard Morse
Senior Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Charles Bair
Partner, San Diego
Andrew Epstein
Special Counsel, Seattle
Rachel Thorn
Of counsel, New York
Wade Andrews
Special Counsel, San Diego
María Álvarez Requejo Heredero
Associate, Brussels
Zhijing Yu
Associate, Singapore
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Chimagen Biosciences Announces Sale of CMG1A46 to GSK

October 29, 2024

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Read more

Related contacts

Marya Postner
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Zack Gong
Associate, Shanghai
Jenny Ge
Associate, Santa Monica
Monica Xu
Special Counsel, Shanghai
Christopher Kimball
Partner, Washington, DC
Rama Padmanabhan
Partner, San Diego
Aaron Pomeroy
Partner, Colorado
Jonathan Rivinus
Partner, Colorado
Rachel Thorn
Of counsel, New York
David Wilson
Partner, London
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Eerik Kukebal
Associate, London
Amanda Pacheco
Associate, Palo Alto
Leo Spicer-Phelps
Partner, London
Lunga Su
Associate, Shanghai
Ivy Wang
Associate, Shanghai
Zhijing Yu
Associate, Singapore
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

View more

Admissions and credentials

New York

Certified Information Privacy Professional/Asia (CIPP/ASIA)